Subtitling task 2, Júlia Creus
0 (0 Likes / 0 Dislikes)
Hello people!
I want to talk to you about
COVID-19 vaccine, ok?
The one developed by
the University of Oxford,
together with AstraZeneca,
which is a company, alright?
Recently, they published
the results for...
so, the overall efficacy of the vaccine,
and the number was
seventy percent.
Now, compared to the other two,
with numbers in the reach of
ninety-ninety five percent,
this looks bad.
However,
it turns out that
they made a mistake,
with about three thousand
people volunteers,
and because they gave to
these people
a lower dose regime of the vaccine.
So, basically, they gave
the same amount of liquid,
but there was less amount
of vaccine in the liquid,
it was diluted.
So,
this was a mistake,
but it turns out,
that when you do that
in the first dose,
and then you give
the full amount on second,
it looks like;
the overall efficacy rises from
seventy to around ninety percent.
Now, taking in to acount,
that this vaccine
is cheaper than the other two,
which is in the reach of
two-three euros
rather than twenty, whatever.
And that it can be stored in fridges,
alright?
At fridge temperature,
around eight degrees positive
rather minus twenty minus eighty.
So, of course,
that all these two characteristics
made this vaccine much better.
So, the only problem
would be the lower efficacy.
But
if it turns out that
the overall efficacy
is actually in the reach of
ninety percent
then that's really good.
So, it looks like
they are going to make
new trials now,
but then, of course,
some people are saying
"No, they are making new ones is because
they did it alright the first time
and so on".
So, it's tricky.